ERBB oncogene proteins as targets for monoclonal antibodies

O. L. Polanovski, E. N. Lebedenko, S. M. Deyev

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

General properties of the family of tyrosine kinase ERBB receptors are considered in connection with their role in the generation of cascades of signal transduction in normal and tumor cells. Causes of acquisition of oncogene features by genes encoding these receptors and their role in tumorigenesis are analyzed. Anti-ERBB monoclonal antibodies approved for therapy are described in detail, and mechanisms of their antitumor activity and development of resistance to them are reviewed. The existing and the most promising strategies for creating and using monoclonal antibodies and their derivatives for therapy of cancer are discussed.

Original languageEnglish
Pages (from-to)227-245
Number of pages19
JournalBiochemistry (Moscow)
Volume77
Issue number3
DOIs
Publication statusPublished - Mar 2012
Externally publishedYes

Fingerprint

Oncogene Proteins
Monoclonal Antibodies
Signal transduction
Gene encoding
Receptor Protein-Tyrosine Kinases
Oncogenes
Protein-Tyrosine Kinases
Tumors
Signal Transduction
Neoplasms
Carcinogenesis
Cells
Derivatives
Therapeutics
Genes

Keywords

  • EGFR
  • HER2/neu
  • Herceptin
  • Receptor tyrosine kinases ERBB1-4
  • Signaling cascades

ASJC Scopus subject areas

  • Biochemistry
  • Medicine(all)

Cite this

ERBB oncogene proteins as targets for monoclonal antibodies. / Polanovski, O. L.; Lebedenko, E. N.; Deyev, S. M.

In: Biochemistry (Moscow), Vol. 77, No. 3, 03.2012, p. 227-245.

Research output: Contribution to journalReview article

Polanovski, O. L. ; Lebedenko, E. N. ; Deyev, S. M. / ERBB oncogene proteins as targets for monoclonal antibodies. In: Biochemistry (Moscow). 2012 ; Vol. 77, No. 3. pp. 227-245.
@article{fbe64afa165e43e18aa106880155c712,
title = "ERBB oncogene proteins as targets for monoclonal antibodies",
abstract = "General properties of the family of tyrosine kinase ERBB receptors are considered in connection with their role in the generation of cascades of signal transduction in normal and tumor cells. Causes of acquisition of oncogene features by genes encoding these receptors and their role in tumorigenesis are analyzed. Anti-ERBB monoclonal antibodies approved for therapy are described in detail, and mechanisms of their antitumor activity and development of resistance to them are reviewed. The existing and the most promising strategies for creating and using monoclonal antibodies and their derivatives for therapy of cancer are discussed.",
keywords = "EGFR, HER2/neu, Herceptin, Receptor tyrosine kinases ERBB1-4, Signaling cascades",
author = "Polanovski, {O. L.} and Lebedenko, {E. N.} and Deyev, {S. M.}",
year = "2012",
month = "3",
doi = "10.1134/S0006297912030029",
language = "English",
volume = "77",
pages = "227--245",
journal = "Biochemistry. Biokhimiia",
issn = "0006-2979",
publisher = "Maik Nauka-Interperiodica Publishing",
number = "3",

}

TY - JOUR

T1 - ERBB oncogene proteins as targets for monoclonal antibodies

AU - Polanovski, O. L.

AU - Lebedenko, E. N.

AU - Deyev, S. M.

PY - 2012/3

Y1 - 2012/3

N2 - General properties of the family of tyrosine kinase ERBB receptors are considered in connection with their role in the generation of cascades of signal transduction in normal and tumor cells. Causes of acquisition of oncogene features by genes encoding these receptors and their role in tumorigenesis are analyzed. Anti-ERBB monoclonal antibodies approved for therapy are described in detail, and mechanisms of their antitumor activity and development of resistance to them are reviewed. The existing and the most promising strategies for creating and using monoclonal antibodies and their derivatives for therapy of cancer are discussed.

AB - General properties of the family of tyrosine kinase ERBB receptors are considered in connection with their role in the generation of cascades of signal transduction in normal and tumor cells. Causes of acquisition of oncogene features by genes encoding these receptors and their role in tumorigenesis are analyzed. Anti-ERBB monoclonal antibodies approved for therapy are described in detail, and mechanisms of their antitumor activity and development of resistance to them are reviewed. The existing and the most promising strategies for creating and using monoclonal antibodies and their derivatives for therapy of cancer are discussed.

KW - EGFR

KW - HER2/neu

KW - Herceptin

KW - Receptor tyrosine kinases ERBB1-4

KW - Signaling cascades

UR - http://www.scopus.com/inward/record.url?scp=84862684871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862684871&partnerID=8YFLogxK

U2 - 10.1134/S0006297912030029

DO - 10.1134/S0006297912030029

M3 - Review article

AN - SCOPUS:84862684871

VL - 77

SP - 227

EP - 245

JO - Biochemistry. Biokhimiia

JF - Biochemistry. Biokhimiia

SN - 0006-2979

IS - 3

ER -